Avidity Biosciences RNA stock is moving higher Wednesday following the company’s announcement that the Phase 1/2 FORTITUDE trial yielded positive results.
The Details: The 39 patient trial was in relation to treating facioscapulohumeral muscular dystrophy (FSHD) with delpacibart braxlosiran.
Data from the trial showed functional improvements across patients with the disease, greater than 50% mean reductions in DUX4 regulated genes and the medicine appears to be well tolerated.
“Data from the FORTITUDE trial are very promising for people living with FSHD as the progression of the disease can make it increasingly difficult to perform critical day-to-day activities, pursue work and can affect many aspects of life, including family and social life,” said Mark Stone, president and chief executive officer of FSHD Society.
“FSHD is one of the most prevalent forms of muscular dystrophy and currently, there are no treatment options. The initial del-brax data offers real hope for those living with the disease, their families, and their caregivers, who are desperately waiting for a treatment.”
Currently, there are no approved therapies for FSHD.
The findings will be presented at the 31st Annual FSHD Society International Research Congress held on June 13-14 in Denver.
Related Link: 12 Health Care Stocks Moving In Wednesday’s Pre-Market Session
RNA Price Action: As of Wednesday morning, Avidity Biosciences shares are trading 33.5% higher at $38.61 per data from Benzinga Pro.
Image: 2860753 from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
